Skip to content

US · NBIX · BIOTECHNOLOGY

Neurocrine Biosciences, Inc. (NBIX) intrinsic value and stock valuation

$150.57as of 2026-11-21 · Mkt cap 16.24B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Neurocrine Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values NBIX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NBIX’s statements →

Neurocrine Biosciences, Inc. Graham Number

Graham Number: $59.48d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 neurocrine.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.86B+22.3% 5y CAGRd
20112025
Net income
$478.6M+3.3% 5y CAGRd
20112025
Free cash flow
$748.7M+28% 5y CAGRd
20112025
Total equity
$3.25B+23.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.86B$2.36B$1.89B$1.49B$1.13B
Operating income$619.1M$570.5M$250.9M$249M$102.5M
Net income$478.6M$341.3M$249.7M$154.5M$89.6M
EPSd$4.67M$3.29M$2.47M$1.56M$915.2K
Operating cash flow$782.7M$595.4M$389.9M$339.4M$256.5M
Capital expenditure-$-34M-$-38.2M-$-28.3M-$-16.5M-$-23.4M
Free cash flow$748.7M$557.2M$361.6M$322.9M$233.1M
Total assets$4.63B$3.72B$3.25B$2.37B$2.07B
Total debt$415.3M$455.1M$428.4M$262.9M$440.4M
Net debt-$-297.7M$222.1M$177.3M$0.00$99.6M
Total equity$3.25B$2.59B$2.23B$1.71B$1.37B
Cash and short-term investments$1.48B$1.08B$1.03B$989.3M$711.3M
Income statement
20252024202320222021
Revenue$2.86B$2.36B$1.89B$1.49B$1.13B
Cost of revenue$52.1M$34M$39.7M$23.2M$14.3M
Gross profit$2.81B$2.32B$1.85B$1.47B$1.12B
Research and development expenses$1.02B$731.1M$565M$463.8M$328.1M
Selling, general and administrative expenses$1.16B$1.01B$887.6M$752.7M$583.3M
Other expenses$17.4M$12.5M$143.9M$0.00$105.3M
Operating expenses$2.19B$1.75B$1.6B$1.22B$1.02B
Cost and expenses$2.24B$1.78B$1.64B$1.24B$1.03B
Interest income$90.3M$91M$0.00$11.2M$0.00
Interest expense$0.00$126.6M$4.6M$7.1M$25.8M
Depreciation and amortization$30.1M$27.1M$21.3M$15.6M$10.9M
Ebitda$666.6M$639.7M$416.1M$236.6M$138.1M
Operating income$619.1M$570.5M$250.9M$249M$102.5M
Total other income/expenses, net$86.3M-$-84.5M$81.2M-$-35.1M-$-1.1M
Income before tax$705.4M$486M$332.1M$213.9M$101.4M
Income tax expense$226.8M$144.7M$82.4M$59.4M$11.8M
Net income$478.6M$341.3M$249.7M$154.5M$89.6M
Weighted average shares outstanding$99.5M$100.4M$97.7M$95.8M$94.6M
Weighted average diluted shares outstanding$102.5M$103.7M$101M$98.9M$97.9M
Balance sheet
20252024202320222021
Cash and short-term investments$1.48B$1.08B$1.03B$989.3M$711.3M
Net receivables$686.8M$479.1M$439.3M$350M$185.5M
Inventory$69M$57.4M$38.3M$35.1M$30.5M
Total current assets$2.52B$1.72B$1.61B$1.45B$972.8M
Property, plant and equipment, net$545.2M$592M$347.3M$145.6M$155.8M
Goodwill and intangible assets$0.00$36.5M$35.5M$37.2M$0.00
Long-term investments$1.18B$864.3M$849.4M$401.5M$624.4M
Total non-current assets$2.11B$1.99B$1.64B$915.2M$1.1B
Total assets$4.63B$3.72B$3.25B$2.37B$2.07B
Accounts payable$104.9M$99.9M$133.3M$67.3M$51.5M
Short-term debt$0.00$0.00$170.1M$169.4M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$743.4M$507.7M$654.8M$537.7M$245.8M
Long-term debt$415.3M$455.1M$258.3M$93.5M$440.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$635M$621.3M$364.6M$123.2M$452.7M
Capital lease obligations$415.3M$455.1M$258.3M$93.5M$105.3M
Total liabilities$1.38B$1.13B$1.02B$660.9M$698.5M
Common stock$100K$100K$100K$100K$100K
Retained earnings$447.7M$29.2M-$-157.1M-$-406.8M-$-635.8M
Accumulated other comprehensive income (loss)$13.1M$5.8M$7M-$-7.9M-$-1.7M
Total equity$3.25B$2.59B$2.23B$1.71B$1.37B
Total investments$1.95B$1.71B$1.63B$1.13B$994.9M
Total debt$415.3M$455.1M$428.4M$262.9M$440.4M
Net debt-$-297.7M$222.1M$177.3M$0.00$99.6M
Cash flow statement
20252024202320222021
Net income$478.6M$341.3M$249.7M$154.5M$89.6M
Depreciation and amortization$30.1M$27.1M$21.3M$15.6M$10.9M
Stock-based compensation$217.9M$195.5M$194.3M$173.1M$134.2M
Change in working capital-$-128.8M-$-19.2M$28.2M-$-67.4M$16.7M
Accounts receivable-$-210.5M-$-39.8M-$-89.3M-$-162.2M-$-28.4M
Inventory-$-15.3M-$-19.1M$5.4M-$-2.6M-$-2.5M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$782.7M$595.4M$389.9M$339.4M$256.5M
Investments in property, plant and equipment-$-34M-$-38.2M-$-28.3M-$-16.5M-$-23.4M
Acquisitions, net$0.00$0.00$0.00-$-42.7M$0.00
Net cash used for investing activities-$-264.4M-$-126.8M-$-467.1M-$-177.1M-$-130.2M
Common stock issued$129.4M$122.1M$65.3M$44.7M$27.5M
Common stock repurchased-$-167.7M-$-300M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-38.3M-$-486.7M$65.3M-$-234.3M$27.4M
Net change in cash$480M-$-18.1M-$-11.6M-$-73.3M$153.7M
Cash at end of period$721M$241M$259.1M$270.7M$344M
Operating cash flow$782.7M$595.4M$389.9M$339.4M$256.5M
Capital expenditure-$-34M-$-38.2M-$-28.3M-$-16.5M-$-23.4M
Free cash flow$748.7M$557.2M$361.6M$322.9M$233.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Neurocrine Biosciences, Inc.

        Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

        CEO
        Kyle W. Gano
        Employees
        2K
        Beta
        0.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Neurocrine Biosciences, Inc. (NBIX)?

        Neurocrine Biosciences, Inc. (NBIX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NBIX undervalued?

        NBIX trades at a price of $150.57 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.